1. Home
  2. NTES vs REGN Comparison

NTES vs REGN Comparison

Compare NTES & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetEase Inc.

NTES

NetEase Inc.

HOLD

Current Price

$117.21

Market Cap

73.3B

Sector

Technology

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$705.46

Market Cap

77.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTES
REGN
Founded
1997
1988
Country
China
United States
Employees
25382
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.3B
77.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
NTES
REGN
Price
$117.21
$705.46
Analyst Decision
Buy
Buy
Analyst Count
3
25
Target Price
$160.00
$830.16
AVG Volume (30 Days)
558.7K
631.5K
Earning Date
05-28-2026
04-29-2026
Dividend Yield
2.61%
0.55%
EPS Growth
N/A
8.19
EPS
N/A
6.75
Revenue
N/A
$5,872,227,000.00
Revenue This Year
$9.57
$12.45
Revenue Next Year
$8.57
$10.13
P/E Ratio
$79.88
$101.40
Revenue Growth
N/A
20.82
52 Week Low
$103.23
$476.49
52 Week High
$159.55
$821.11

Technical Indicators

Market Signals
Indicator
NTES
REGN
Relative Strength Index (RSI) 58.10 37.99
Support Level $108.71 $689.88
Resistance Level $119.72 $783.87
Average True Range (ATR) 2.02 18.92
MACD 0.25 -5.59
Stochastic Oscillator 80.13 37.86

Price Performance

Historical Comparison
NTES
REGN

About NTES NetEase Inc.

Founded in the late 1990s as an internet portal, NetEase has evolved into China's second-largest online gaming company. Its early success was anchored by the massively multiplayer online role-playing game Fantasy Westward Journey, which laid the foundation for a durable franchise strategy. Over the past decade, the company has expanded its portfolio with successful titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which continue to maintain sizable and engaged player bases.In addition to its in-house development capabilities, NetEase partners with global IP holders such as Microsoft and Marvel to develop and publish titles based on established franchises, including World of Warcraft, Diablo Immortal, and Marvel Rivals, further strengthening its global presence.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: